?? Patients, Scientists Agree: Automated Red Blood Cell Exchange Enhances Quality of Life in Sickle Cell Disease Patients Sickle cell disease (SCD) — it’s a genetic blood disorder affecting millions globally. Patients with #SCD live with the looming threat of acute pain crises that could land them in the hospital. And many struggle to find ways to prevent #pain and other dangerous complications. Terumo Blood and Cell Technologies is committed to supporting these patients with SCD through a multi-pronged approach: partnering with patient advocacy and policy groups, raising awareness, providing our expertise on automated red blood cell exchange (aRBCX), and more. We are excited to share that our team has recently demonstrated the impact of #aRBCX for SCD. Based on 20 years of data, we’ve found aRBCX leads to shorter hospital stays, fewer pain-related hospitalizations, and reduced procedure times. Ultimately, this is deemed to positively influence the #QOL for patients with SCD. “As gene therapies and drug treatments target permanent cures for sickle cell disease, red blood cell exchange remains a high-impact treatment to improve quality of life for Sickle Cell Warriors around the globe,” comments Antoinette Gawin, President and CEO of Terumo Blood and Cell Technologies. ??Read more on how we are working to improve care for patients with SCD: https://bit.ly/3OkF3i2 ??Read the full research here: https://bit.ly/497Cs4r #SickleCell #PatientAccess #SickleCellAwareness #SickleCellWarrior #AutomatedRedBloodCellExchange #Apheresis
Terumo Blood and Cell Technologies
医疗设备制造业
Lakewood，Colorado 81,889 位关注者
The official LinkedIn page of Terumo Blood and Cell Technologies. Contributing to Society Through Healthcare
关于我们
Headquartered in Lakewood, Colorado, Terumo Blood and Cell Technologies is a global leader in blood component, therapeutic apheresis and cellular technologies serving customers in more than 130 countries. As the only company with the unique combination of apheresis collections, manual and automated whole blood processing and pathogen reduction, we believe in the potential of blood to do even more for patients than it does today. This belief unites our organization, inspires our innovation and strengthens our collaboration with customers. Originally established in 1964 as COBE Laboratories, today, nearly 7,000 associates around the world are deeply committed to our vision of working together for better lives and our promise to unlock the potential of blood and cells. One way we back these words is through our pledge to be a conscientious corporate citizen and conduct our business in a way that provides social, environmental and economic benefit. At Terumo Blood and Cell Technologies, discovery never stops. We share a passion for thinking in new and different ways and we are proud to support education and research through a variety of community involvement activities as well as by providing grants to advance treatment options for patients. We know the work we do matters and has the potential to fundamentally improve health care. We remain dedicated to ensuring the lifesaving gift of blood is available around the world and to meeting and exceeding the needs of our customers and the patients we ultimately serve. If you are the best at what you do, we invite you to explore career opportunities with us now! We have careers in: ? R&D ? IT ? Engineering ? Clinical Sciences ? Manufacturing ? Software Development ? Quality and Regulatory Social Media Policy: https://www.terumo.com/socialmedia_policy
- 网站
-
https://www.terumobct.com
Terumo Blood and Cell Technologies的外部链接
- 所属行业
- 医疗设备制造业
- 规模
- 5,001-10,000 人
- 总部
- Lakewood，Colorado
- 类型
- 上市公司
- 创立
- 1964
- 领域
- blood component separation and processing、therapeutic apheresis、cellular technologies和regenerative medicine
产品
地点
-
主要
获取路线
11158 W Collins Ave
US，Colorado，Lakewood，80215
Terumo Blood and Cell Technologies员工
动态
-
Terumo Blood and Cell Technologies转发了
Senior Vice President & General Manager, Global Blood Solutions @ Terumo Blood and Cell Technologies & Managing Director & Board Chair @ Terumo Penpol
Pleased to bring this innovative and disruptive technology to our customers in in the U.S. ! #wholebloodautomation #reveos
?? From the AABB Annual Meeting's show floor, Terumo Blood and Cell Technologies' Chetan Makam introduces the Reveos? Automated Blood Processing System to IBTV as a disruptive technology, explaining how this technology contributes to addressing the platelet shortage. Chetan goes on to discuss further challenges associated with blood processing, including operational efficiencies, donor issues as well as attracting and retaining the right talent. ? Watch the full Movers & Shakers series from AABB, here: https://lnkd.in/edkPYdep #AABB #AABB24 #BloodIsAnEssentialMedicine #ImportanceOfBlood #BloodProcessing #BloodDonation
-
??♀???We're still on that runner's high ????♀? Recently, 80 associates and their families from Terumo Blood and Cell Technologies and Terumo Europe joined forces for the annual Ekiden race in Brussels. Not only was it a great experience to bond and get some exercise, but we also raised €10,000 as a team. Terumo BCT donated the raised funds to Africa Sickle Cell Organization (ASCO) to support their activities to help drive awareness, research, and support for those affected by sickle cell disease. #TerumoProud #SickleCellDisease #SCD #SickleCellAwareness
-
-
-
-
-
+1
-
-
Hace unas semanas, junto a un grupo de clientes finales de Sudamérica y Centroamérica, tuvimos el honor de realizar una visita guiada al Instituto Distrital de Ciencia, Biotecnología e Innovación en Salud - IDCBIS. Fuimos recibidos por el Dr Gustavo Salguero, Director del Instituto y por Patricia Forero, Directora Técnica del Banco de Sangre Distrital, quienes nos brindaron una cálida bienvenida y la oportunidad de conocer de primera mano el destacado trabajo de esta institución. El #IDCBIS es un referente tanto a nivel nacional como internacional en la formación de talento humano en salud. Es la única institución en Colombia que asegura la calidad y seguridad de los hemocomponentes mediante pruebas de biología molecular (NAT) al 100% de los componentes sanguíneos, detectando virus como VIH, Hepatitis B y Hepatitis C. Nos enorgullece contar en nuestra región con una entidad de este nivel de innovación y compromiso en salud pública. Agradecemos al IDCBIS por inspirarnos y por liderar el camino hacia una medicina transfusional más segura. #Innovatur #BancoDeSangre #MedicinaTransfusional #InnovaciónEnSalud
-
-
?? Hear from Chetan Makam, General Manager, Global Blood Solutions, why we are so excited about launching the Reveos Automated Blood Processing System in the U.S. Reveos can help blood centers on multiple fronts such as: 1?? Improving operational efficiency 2?? Maximizing the yield of whole blood donations 3?? Easing labor force pressures What excites you the most about this innovation? Let us know in the comments ?? Thanks, IBTV for the interview. #AABB #AABB24 #BloodProcessing #BloodDonation #Platelets
?? From the AABB Annual Meeting's show floor, Terumo Blood and Cell Technologies' Chetan Makam introduces the Reveos? Automated Blood Processing System to IBTV as a disruptive technology, explaining how this technology contributes to addressing the platelet shortage. Chetan goes on to discuss further challenges associated with blood processing, including operational efficiencies, donor issues as well as attracting and retaining the right talent. ? Watch the full Movers & Shakers series from AABB, here: https://lnkd.in/edkPYdep #AABB #AABB24 #BloodIsAnEssentialMedicine #ImportanceOfBlood #BloodProcessing #BloodDonation
-
Junte-se a nós para um encontro com especialistas em hematologia e medicina transfusional, onde exploraremos os últimos avan?os no uso da eritrocitaféresis e da troca plasmática terapêutica em pacientes pediátricos. Neste evento, teremos a oportunidade de discutir indica??es clínicas, gerenciamento de efeitos adversos e resolu??o de casos. N?o perca esta oportunidade! ?? Agenda Eritrocitaférese em Pediatria: Princípios, Indica??es e Resultados Dra. Patricia Moura – Brasil Médica especialista em Hematologia Pediátrica e Hemoterapia Estratégias para Troca Plasmática Terapêutica em Pacientes Pediátricos: Estudos de Caso Dr. Felipe Lemos – Uruguai Médico especialista em Medicina Transfusional Registre-se ?? https://bit.ly/3O6Bax1 ?? 26 de novembro, 2024 México e América Central: 3:30 às 5:00 p.m. Col?mbia e Peru: 4:30 às 6:00 p.m. Brasil, Argentina, Uruguai, Chile, Paraguai: 6:30 às 8:00 p.m.
-
-
Acompá?enos en un encuentro con especialistas en hematología y medicina transfusional, donde exploraremos los avances más recientes sobre la utilización de la eritrocitaféresis y del recambio plasmático terapéutico en pacientes pediátricos. En este evento, tendremos la oportunidad de discutir las indicaciones clínicas, el manejo de efectos adversos y la resolución de casos clínicos. ?No se pierda esta oportunidad! ?? Agenda Eritrocitaféresis en pediatría: principios, indicaciones y resultados Dra. Patricia Moura – Brasil Médica especialista en Hematología y Hemoterapia Pediátrica Estrategias para el recambio plasmático terapéutico en pacientes pediátricos: estudio de casos Dr. Felipe Lemos – Uruguay Médico especialista en Medicina Transfusional Vea la agenda completa y regístrese aquí ?? https://bit.ly/4ftl7Fm ?? Noviembre 26, 2024 México y América Central: 3:30 a 5:00 p.m. Colombia y Perú: 4:30 a 6:00 p.m. Brasil, Argentina, Uruguay, Chile, Paraguay: 6:30 a 8:00 p.m.
-
-
We are looking forward to this webinar with International Society of Blood Transfusion (ISBT) where we will be discussing Strategies to Maintain a Sustainable Supply of Platelets! Save your seat by registering at the link in the post below!
ISBT Corporate Partner Webinar with Terumo Blood and Cell Technologies ?? Strategies to Maintain a Sustainable Supply of Platelets?? ?? 2:00 PM - 3:00 PM CET?? ?? 28 November 2024 ?? Join us for a global discussion on innovative strategies blood establishments are using to sustain platelet supplies during times of low donation rates, influenced by factors like demographic shifts and pandemic impacts. This session is ideal for anyone involved in transfusion services and blood component management. Audience:?? Blood bank staff, scientists, transfusion practitioners, Masters & PhD students, and even blood donors looking to learn more! Speaker: Lacey Johnson, Principal Research Fellow at the Australian Red Cross Lifeblood ?? Register Now for Free Access and boost your understanding of sustainable transfusion practices! https://lnkd.in/dJsYMV42
-
-
??Today, we celebrate a truly special moment for Terumo Blood and Cell Technologies! Our President and CEO, Antoinette Gawin, has been honored with the Denver Business Journal's Most Admired CEO Award. This award, accepted by her daughter on her behalf, is a testament to her visionary leadership and her dedication to advancing healthcare across the globe. Since stepping into her role in 2019, Antoinette has guided Terumo BCT through a remarkable journey of growth and innovation. Under her leadership, we’ve expanded beyond our core blood banking foundations to support the rapidly evolving fields of cell and gene therapy and plasma innovations. With a strengthened global manufacturing presence and a new Patient Access Team, we’re more equipped than ever to deliver life-saving solutions worldwide. Please join us in celebrating Antoinette's well-deserved recognition and her exceptional impact on our industry and community! Read more at: https://bit.ly/3OhNTNb #TerumoBCT #OneTerumo
-
-
?? Celebrating a New Chapter in China ?? On November 14, 2024, we officially launched our localization initiative in China. Under the theme “Unlocking a New Chapter in China, Led by Purpose, Built on Quality” this milestone event brought together leaders from Terumo BCT, Terumo Corporation, Terumo China Holdings, and government representatives – all united in our commitment to "in China, for China." ? Highlights from the ceremony? - Announced our strategic partnership with Terumo Medical Products (Hangzhou) Co., Ltd (TMPH) for local manufacturing. - Committed $15M investment by 2025 to expand our business in China and support localized production of Trima Accel? and Spectra Optia? systems and disposable sets. - Strengthened ties within the Terumo Group as #OneTerumo. TMPH will be uniquely positioned to produce products from all three Terumo Companies—Cardiac and Vascular, Medical Care Solutions, and Blood and Cell Technologies . This initiative is more than just expanding our manufacturing capability. By establishing a stable and flexible local supply chain while maintaining global quality standards through unified quality management, we are positioning ourselves to better serve our Chinese customers and patients. A huge thank you to everyone who contributed to this milestone! Here’s to unlocking the potential of blood and cells for more patients in China. For full press release: (English): https://bit.ly/4fIUHiQ (Chinese): https://bit.ly/4fqk353 #TerumoBCT #ChinaLaunch #Localization #UnlockingPotential #TerumoProud #PatientCare
-